A Single Arm Clinical Evaluation of Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Medtronic
- 03 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.
- 23 Mar 2018 New trial record